Literature DB >> 3576678

Induction of contraction in isolated rat aorta by cyclosporine.

H Xue, R D Bukoski, D A McCarron, W M Bennett.   

Abstract

Cyclosporine (CsA) is a new immunosuppressive agent that has adverse effects of nephrotoxicity and de novo appearance of hypertension. It has been hypothesized that the mechanism of the contrary effects is through an action of CsA on vascular smooth muscle. To test this hypothesis, thoracic aortas were isolated from Wistar Kyoto rats and ring segments prepared for measurement of tension. CsA (5 X 10(-6) M) induced a slow increase in tone of the isolated rings with a response at 3 hr of 0.70 +/- 0.17 N/m2 X 10(4). This contraction was significantly inhibited by the Ca2+ channel blocker verapamil (0.30 +/- 0.08 N/m2 X 10(4) after 3 hr, P less than 0.05) and by the noncompetitive alpha-antagonist phenoxybenzamine (0.06 +/- 0.07 N/m2 X 10(4) after 3 hr, P less than 0.05). The competitive alpha-antagonist phentolamine had mixed effects. CsA does not irreversibly alter vascular smooth muscle contractile ability since a 3 hr exposure to the agent had no effect on either the maximal contractile response or sensitivity to KCl. We conclude that CsA can directly induce contraction in vascular smooth muscle, perhaps by inducing a release of norepinephrine from adrenergic nerve terminals. The data are consistent with the hypothesis that CsA induces nephrotoxicity and de novo hypertension through a contractile effect on vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3576678     DOI: 10.1097/00007890-198705000-00022

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

4.  Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries.

Authors:  G S O'Neil; A H Chester; S Kushwaha; M Rose; S Tadjkarimi; M H Yacoub
Journal:  Br Heart J       Date:  1991-09

5.  Cyclosporine-induced nephrotoxicity in deoxycorticosterone-NaCl treated rats.

Authors:  J M Wyss; M S Mozaffari; P L St John; D R Abrahamson
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

6.  Vascular mechanisms of cyclosporin-induced hypertension in the rat.

Authors:  J B Roullet; H Xue; D A McCarron; S Holcomb; W M Bennett
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

7.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02

8.  Cyclosporine A enhances total cell calcium independent of Na-K-ATPase in vascular smooth muscle cells.

Authors:  D Bokemeyer; U Friedrichs; A Bäcker; H J Kramer; H Meyer-Lehnert
Journal:  Clin Investig       Date:  1994-12

9.  Cyclosporin associated headache.

Authors:  M J Steiger; T Farrah; K Rolles; P Harvey; A K Burroughs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

Review 10.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.